Scynexis (SCYX) Change in Cash (2013 - 2026)
Scynexis' (SCYX) quarterly Change in Cash came in at -$26.2 million in Q2 2026, down 793.07% on a YoY basis from $3.8 million in Q2 2025, and down 269.89% quarter-over-quarter from $15.4 million in Q1 2026.
Analysis
Scynexis (SCYX) Change in Cash (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Change in Cash for 14 consecutive years, with -$26.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Cash fell 793.07% year-over-year to -$26.2 million; the trailing twelve-month figure through Jun 2026 stood at -$588000.0 (up 96.15% YoY), and the FY2025 full-year result was $4.9 million, up 126.96% from the prior year.
- Change in Cash declined to -$26.2 million in Q2 2026 per SCYX's latest filing, from $15.4 million in the prior quarter.
- Across five years, Change in Cash topped out at $31.4 million in Q2 2023 and bottomed at -$50.1 million in Q3 2022.
- Historically, Change in Cash has averaged -$5.2 million across 5 years, with a median of -$9.2 million in 2022.
- The sharpest annual moves came in 2022 and 2026: Change in Cash slumped 800.39% in 2022, then surged 269.2% in 2026.
- Over 5 years, Change in Cash stood at -$22.8 million in 2022, then soared by 56.06% to -$10.0 million in 2023, then slipped by 26.51% to -$12.7 million in 2024, then surged by 150.97% to $6.5 million in 2025, then sank by 505.2% to -$26.2 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered -$26.2 million, $15.4 million, and $6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -4.45 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 649.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -504.60 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -185.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -170.44 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -26.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.18 Mn |
| Mar 31, 2026 | 15.41 Mn |
| Dec 31, 2025 | 6.46 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Mar 31, 2025 | -9.11 Mn |
| Dec 31, 2024 | -12.68 Mn |
| Sep 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | -9.49 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | -10.02 Mn |
| Sep 30, 2023 | -13.89 Mn |
| Jun 30, 2023 | 31.37 Mn |
| Mar 31, 2023 | -18.90 Mn |
| Dec 31, 2022 | -22.81 Mn |
| Sep 30, 2022 | -50.07 Mn |
| Jun 30, 2022 | 23.48 Mn |
| Mar 31, 2022 | -9.27 Mn |
| Dec 31, 2021 | 4.38 Mn |
| Sep 30, 2021 | -12.39 Mn |